ARDELYX, INC. Repayments of Secured Debt
ARDELYX, INC. (ARDX) reported Repayments of Secured Debt of $33.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfSecuredDebt · last filed 2026-08-06
- ARDELYX, INC. repayments of secured debt for the quarter ending 2023-12-31 was $0.00.
- ARDELYX, INC. repayments of secured debt for the quarter ending 2023-09-30 was $0.00.
- ARDELYX, INC. repayments of secured debt for the quarter ending 2023-06-30 was $0.00.
- ARDELYX, INC. repayments of secured debt for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- ARDELYX, INC. repayments of secured debt for fiscal 2024 was $0.00.
- ARDELYX, INC. repayments of secured debt for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- ARDELYX, INC. repayments of secured debt for fiscal 2022 was $33.04M, a 69.91% increase from fiscal 2021.
- ARDELYX, INC. repayments of secured debt for fiscal 2021 was $19.44M, a 15455.20% increase from fiscal 2020.
| Period end | Repayments of Secured Debt 3 month | Repayments of Secured Debt 6 month | Repayments of Secured Debt 9 month | Repayments of Secured Debt 12 month | Repayments of Secured Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $33.83M 10-Q · filed 2026-08-06 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $0.00 10-K · filed 2025-02-20 | ||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 10-K · filed 2025-02-20 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $0.00 10-Q · filed 2023-10-31 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 10-Q · filed 2023-08-02 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 | |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-03 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $0.00 derived: sum of 4 quarters · filed 2025-02-20 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $0.00 derived: sum of 2 quarters · filed 2025-02-20 | $0.00 derived: sum of 3 quarters · filed 2025-02-20 | $33.04M 10-K · filed 2025-02-20 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $0.00 derived: sum of 2 quarters · filed 2023-10-31 | $33.04M 10-Q · filed 2023-10-31 | $52.48M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $33.04M 10-Q · filed 2023-08-02 | $52.48M derived: sum of 3 quarters · filed 2024-02-22 | $52.48M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2022-03-31 | $33.04M 10-Q · filed 2023-05-03 | $52.48M derived: sum of 2 quarters · filed 2024-02-22 | $52.48M derived: sum of 3 quarters · filed 2024-02-22 | $52.48M derived: sum of 4 quarters · filed 2024-02-22 | |
| 2021-12-31 | $19.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $19.44M derived: sum of 2 quarters · filed 2024-02-22 | $19.44M derived: sum of 3 quarters · filed 2024-02-22 | $19.44M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 derived: sum of 2 quarters · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $125.00K 10-K · filed 2023-03-02 | $0.00 10-K · filed 2022-02-28 | |||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |